Book summary “The science of marijuana”: summary

Introduction

You live in a society shaped by centuries of emotional debate, legal prohibition, and medical confusion regarding cannabis. Modern science struggles to separate the political myths of the past from the actual pharmacological realities of the plant. You need objective facts to understand how cannabis interacts with your body and mind.

Leslie L. Iversen provides a comprehensive scientific examination of cannabis pharmacology, neurobiology, medical applications, and public policy.

The book explores how the plant works at a molecular level and evaluates its actual risks and therapeutic value. You will discover the answers to several key questions:

• How does the human brain process the active compounds of cannabis?
• What are the true physical and psychological effects of intoxication?
• How do endogenous cannabinoids regulate basic bodily functions?
• What medical conditions might benefit from cannabinoid therapies?

1. History and the Plant

Cannabis boasts a multi-millennial history of industrial, medical, and ritual use, culminating in modern cultivation techniques that yield high concentrations of psychoactive cannabinoids. You can trace the earliest evidence of hemp cord impressions back to approximately 10,000 BC in Taiwan. Ancient Chinese texts like the Pen-ts'ao describe its intoxicant and pain-relieving properties.

Cannabis has a multi-millennial history spanning early industrial hemp cultivation in Asia and medical or ritual use across diverse ancient civilizations.

Nomadic tribes and religious traditions, such as the worship of Lord Siva in India, incorporated cannabis preparations into their cultures long before it reached Western societies. Early American settlers widely cultivated hemp to supply fiber for ropes and canvas. Until the 1880s almost all of the world's paper was manufactured from hemp.

Ancient Indian legend tells how the Hindu god Siva ate leaves from the plant after seeking shelter under it, adopting it as his favorite food and becoming known as the Lord of bhang.

From Ancient Cultivation to Prohibition

During the mid-nineteenth century, a circle of European writers and poets popularized hashish experimentation and documented its psychological effects. French intellectuals in Paris formed the Club des Hashischins, utilizing hashish as an escape from bourgeois life. They described enhanced sensory perceptions, synesthesia, and vivid hallucinations in their literary works.

French author Pierre Gautier founded the Club des Hashischins and described feeling that his body had dissolved and become transparent after consuming hashish.

The criminalization of marijuana in the United States was driven by political campaigns in the 1930s that led to a federal ban and halted scientific research for decades. Harry J. Anslinger, head of the Federal Bureau of Narcotics, utilized sensational media narratives linking marijuana to violent crime. He pointed to the historical Assassins to lobby for prohibition, culminating in federal legislation that outlawed medical use and stopped research.

Harry Anslinger wrote magazine articles drawing historical parallels between modern marijuana users and the 11th-century religious order of the Assassins to warn against the drug.

The US Congress passed the Marijuana Tax Act in 1937, removing twenty-eight different pharmaceutical preparations available to American physicians. The twenty-first century has experienced a major legal and medical revival of cannabis alongside changing societal attitudes toward recreational use. Numerous US states and European countries have legalized medical cannabis or authorized adult recreational use. By the turn of the century, thirty-one US states approved propositions making marijuana available for medical use, while an estimated twenty million regular users consumed cannabis in the United States and Europe by 2016 alongside six hundred forty-three thousand related arrests.

Botany and Cannabinoid Chemistry

The cannabis plant produces over one hundred cannabinoid chemicals in specialized glandular structures, with delta-9-tetrahydrocannabinol acting as the main psychoactive agent. Cannabis sativa and Cannabis indica are fast-growing annual plants that concentrate their resin and THC primarily in fine droplets produced by glandular hairs on female flower heads. While male plants produce pollen and seeds, seedless female flower heads are cultivated to maximize potency. Indoor plants reach maturity in sixty days under optimum heat and light, while outdoor cultivation requires three to five months.

Traditional cultivators in India employed expert ganja doctors to cut down male plants in hemp fields before they could flower to ensure the production of resin-rich sterile female flowering heads.

The diverse aroma profiles and psychoactive qualities of different cannabis strains are influenced by volatile hydrocarbons known as terpenes. Terpenes are secreted by the same glands that produce THC and CBD, imparting distinct scents such as citrus, berry, mint, and pine. Evidence suggests these compounds contribute to the specific subjective and psychoactive effects associated with different plant varieties. Researchers identified over one hundred different terpenes in the cannabis plant, each contributing to a unique aromatic profile across strains.

Modern extraction methods and indoor cultivation techniques have yielded a wide spectrum of cannabis preparations with drastically varying THC concentrations:

• herbal marijuana leaves and small stems contain 4 to 6 percent THC;
• female flower buds contain 10 to 30 percent THC;
• compressed resin contains 15 to 25 percent THC;
• solvent-extracted concentrates reach 40 to 80 percent THC.

2. Pharmacology and Receptors

The isolation of delta-9-THC and the subsequent discovery of specific G-protein coupled cannabinoid receptors revealed the molecular basis of cannabis action in the brain.

Isolating THC and Administration Routes

Early Victorian chemists failed to isolate the active ingredient using standard acid-base extraction methods because cannabis resin lacks acidic or basic properties and cannot be crystallized. True progress required organic solvents like alcohol and petroleum ether, leading eventually to the identification of delta-9-THC by Gaoni and Mechoulam.

In 1897, Cambridge researcher Dr. C. R. Marshall ingested 0.1 to 0.15 grams of a red oil extract, experiencing acute intoxication, uncontrollable laughter, and a complete loss of time relation. He took a 50 mg dose three weeks after his initial experiment. Mechoulam and Gaoni spent 5 to 6 years on hashish research.

The viscous resin named cannabinin made up 6% or 7% of weight of the starting material. Wood, Spivey, and Easterfield isolated a red oil or resin with a 265°C boiling point.

The route of administration drastically alters the pharmacokinetics, bioavailability, and subjective intensity of cannabis effects. Smoking and vaping deliver THC rapidly to the brain via the lungs within seconds, allowing you to titrate your dose effectively. Conversely, oral ingestion results in slow, unpredictable absorption and extensive first-pass liver metabolism, which produces the active metabolite 11-hydroxy-THC.

Clinical pharmacokinetic studies showed that smoking two identical marijuana cigarettes generated rapid peak blood levels, while oral administration delayed peak plasma concentrations to between 1 and 4 hours. THC reaches a 200°C boiling point during smoking and vaporization. Agurell et al. used marijuana cigarettes containing 9 mg of THC in their pharmacokinetic study. You absorb an average of 20% of total THC in a marijuana cigarette, with an actual absorption range of 10% to 30% among experienced smokers.

Fat-soluble THC and its metabolites have a long elimination half-life and accumulate in body fat, allowing sensitive tests to detect inactive metabolites weeks after use. Because THC is highly lipid-soluble, it rapidly leaves the blood and sequesters into adipose tissues, yielding an overall elimination half-life of 3 to 5 days. While unchanged THC clears quickly, inactive metabolites like 11-nor-carboxy-THC persist in urine for weeks, necessitating saliva testing for recent intoxication.

British police forces implemented roadside immunoassay test kits in March 2015 to detect THC in saliva as an indicator of recent driving under the influence. Cannabinoids have an overall elimination half-life of 3 to 5 days. One-third of cannabinoids are excreted in urine, while two-thirds are excreted in feces. Various US states set 5 ng THC/ml saliva and 25 ng THC/ml saliva as contentious upper limits.

Decades of academic research into cannabinoid structure-activity relationships enabled underground chemists to synthesize potent full agonists for the recreational market known as legal highs. Academic and pharmaceutical laboratories synthesized hundreds of THC analogs to study structure-activity relationships. This published data was subsequently exploited to create synthetic cannabinoids such as JWH-018, which were sprayed on herbal mixtures and sold as legal highs under names like Spice and K2.

In 2008, German researchers revealed that innocuous herbal mixtures sold as Spice were laced with synthetic cannabinoids like JWH-018. Third-generation compounds BB-22 and FU-BB-22 are 30 times more potent compared to JWH-018. These third-generation synthetic cannabinoids exhibited a 0.1 nM binding affinity for CB-1 receptors.

Discovery of CB-1 and CB-2 Receptors

The identification of specific G-protein coupled cannabinoid receptors explained how tiny physiological amounts of THC produce profound psychoactive effects.

Instead of acting via non-specific membrane disruption, THC targets specific receptors that inhibit adenylate cyclase and cyclic AMP formation. Using radiolabeled synthetic compounds like CP-55,940, researchers successfully isolated and cloned the gene for the CB-1 receptor in the brain.

Allyn Howlett and her colleagues discovered in 1986 that cannabinoids inhibit adenylate cyclase activity in rat brain tissue cultures. An average marijuana joint contains 40 to 100 mg of THC. A maximum estimated 1,000 micrograms of THC reaches the brain. THC has a 1.6 nM concentration for half occupancy (Ki) at the CB-1 receptor, and (-)CP-55,940 has a Ki of 0.068 nM.

Cannabinoid receptor subtypes exhibit distinct anatomical distributions, accounting for the wide array of central and peripheral effects produced by cannabis. CB-1 receptors are densely located presynaptically in the brain's cerebellum, basal ganglia, hippocampus, and cerebral cortex, while being sparse in the brainstem, which explains the absence of fatal respiratory depression. CB-2 receptors are localized primarily in peripheral immune tissues and white blood cells.

Autoradiographic mapping using tritium-labeled CP-55,940 on rat brain sections demonstrated complete absence of binding sites in genetically modified CB-1 knockout mice. DNA sequence database searches described 140 novel G-protein coupled receptors.

3. Biological Effects of Cannabinoids

Cannabinoids alter neurotransmitter release, cardiovascular function, and cognitive processes, producing a distinct spectrum of subjective intoxication and behavioral changes.

Neurotransmission and Physiological Changes

Activation of CB-1 receptors by THC inhibits the release of various neurotransmitters from nerve terminals. CB-1 receptors are concentrated on nerve terminals rather than cell bodies. Their activation inhibits N-subtype calcium ion channels, which are essential for releasing neurotransmitters such as GABA, noradrenaline, and acetylcholine at synapses. Although this generally dampens neural activity, it can disinhibit other circuits, selectively increasing dopamine and endorphin release in the nucleus accumbens.

THC causes significant cardiovascular changes, primarily increasing heart rate and lowering blood pressure through arterial vasodilation. In conscious animals and humans, THC relaxes smooth muscle in arteries, causing vasodilation that lowers blood pressure. This drop triggers a compensatory increase in resting heart rate. These effects are mediated directly by peripheral CB-1 receptors in blood vessels and the heart, as they are absent in CB-1 knockout mice and blocked by rimonabant.

Reddening of the eyes caused by dilated conjunctival blood vessels is a visible sign of THC-induced vasodilation in humans. A vehicle solution used to dissolve THC for intravenous administration contains 0.4-1.0% Tween-80 and 0.4-1.0% ethanol in saline. This intravenous administration results in a 60% increase over the resting pulse rate, which is an equivalent cardiac increase observed in humans after THC use.

Cannabinoids provide pain relief through both central nervous system pathways and peripheral tissue mechanisms. THC and synthetic cannabinoids reduce acute and chronic pain by acting on CB-1 receptors located in primary sensory neurons, the spinal cord, and brainstem. While parallel to opiate systems, cannabinoid and opiate analgesia can act synergistically. Peripheral sites and CB-2 receptors also contribute to pain control and anti-inflammatory responses.

Low doses of THC that were independently ineffective made animals more sensitive to low doses of morphine in mouse tail-flick tests and rat arthritis models. Professor Billy Martin devised a test battery measuring reduced motility, lowered body temperature, analgesia, and immobility in mice. Strong correlations exist between cannabinoid potency in these tests, their in vitro binding affinities for CB-1 receptors, and their psychoactivity in humans.

Researchers tested 25 cannabinoid analogs against radioactively labeled CP-55,940 binding assays. High doses of cannabinoids alter animal motility and posture, producing hyperreflexia and catalepsy. In small animals, low doses of THC reduce spontaneous running activity while triggering sudden bursts of reflex activity, while higher doses induce catalepsy where animals remain unmoving in unnatural postures. These changes reflect actions on CB-1 receptors within the basal ganglia and cerebellum.

Adams and Martin described mice jumping in response to stimuli like corn popping in a popcorn machine, while Dixon described dogs and cats showing awkward gaits and swaying movements. A subcutaneous dose of WIN-55,212-2 of 0.3 mg/kg was used to train rats in discriminative stimulus tests.

Cognitive Impairment and Subjective Experience

Cannabis produces consistent acute disruptions in short-term working memory and executive function, while subjective highs progress through euphoria and altered time perception.

Acute intoxication impairs working memory, attention, and information processing by disrupting neural circuits in the frontal cortex and hippocampus. Residual executive function deficits can persist for weeks following heavy use, including impairments in decision-making, planning, and concept formation.

In a 25-year US cohort study involving 3000 people, cumulative lifetime exposure to cannabis showed progressive impairment in verbal memory, equivalent to remembering one word less from a 15-word list for every 5 years of previous use.

The subjective cannabis high progresses through distinct phases characterized by euphoria, altered time perception, and sensory distortions. Intoxication involves an initial buzz, a high characterized by euphoria, heightened humor, and distorted time perception where time seems drawn out, and potentially a stoned state involving deep introspection or synesthesia. These psychological effects are blocked entirely by the CB-1 antagonist rimonabant, which was tested in a controlled psychological study with 63 healthy cannabis users who received rimonabant or placebo.

Fitz Hugh Ludlow in The Hasheesh Eater described expansive sensations of space, journeying through heavenly territories, and occasional terrifying hallucinations. Ludlow first encountered marijuana in a local pharmacy at age 16.

Animal drug discrimination tests show that cannabinoids produce a unique, recognizable spectrum of central nervous system effects. Rats and monkeys trained to press levers for food rewards learn to discriminate cannabinoids from saline. They generalize their responses across various phytocannabinoids and synthetic cannabinoids but fail to generalize to other classes of CNS drugs like morphine, psilocybin, or benzodiazepines.

Rats trained to recognize a subcutaneous dose of 0.032 mg/kg of WIN-55,212-2 successfully recognized lower doses of CP-55,940 and oral THC, while cannabis resin smoke fully generalized to THC. A subcutaneous dose of 0.007 mg/kg of CP-55,940 was also recognized by trained rats.

4. The Endocannabinoid System

The brain produces its own endogenous cannabinoid ligands that serve as retrograde messengers to regulate synaptic transmission, energy metabolism, and pain.

Following the discovery of the cannabis receptor, researchers searched for natural ligands and identified anandamide, 2-arachidonylglycerol (2-AG), and several other related compounds that act on cannabinoid receptors. As of July 2017, PubMed lists over 6,000 scientific publications involving endocannabinoids. You can count 13 endocannabinoids currently known alongside the 21-carbon substances found in cannabis plant extracts.

Mechoulam and colleagues identified 2-AG and anandamide, demonstrating they possess THC-like pharmacological and behavioral actions in animal models.

Unlike stored neurotransmitters, endocannabinoids are produced through calcium influx triggered by neuronal activation and are broken down by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL) to prevent persistent receptor activation.

Endocannabinoid Discovery and Retrograde Signaling

Released from postsynaptic neurons, these lipid messengers travel back to presynaptic terminals to suppress both inhibitory and excitatory inputs, a mechanism underlying phenomena like depolarization-induced suppression of inhibition (DSI). DSI suppression duration lasts up to 10 seconds or more.

Wilson and Nicoll used rat hippocampal slice preparations and showed that DSI was completely blocked by CB-1 receptor antagonists AM251 and rimonabant, and that depolarizing a neuron caused DSI to affect adjacent neurons up to 20 micrometers away, covering a sphere of influence 40 micrometers in diameter.

Metabolic Control and Pharmacological Potential

Hypothalamic endocannabinoids and receptors in fat tissues, liver, and pancreas control energy metabolism, insulin secretion, and the balance between hunger and satiety hormones. Osei-Hyiaman et al. and Bellocchio et al. showed that CB-1 receptors in fat tissues and the liver play an important role in regulating fat synthesis.

Compounds like anandamide interact with TRPV-1 receptors to influence pain pathways, and stress triggers rapid endocannabinoid accumulation in the periaqueductal gray to induce stress-induced analgesia. Morena et al. showed that in an animal model of stress-induced analgesia, much of the effect was blocked by rimonabant following rapid accumulation of anandamide and 2-AG in the brainstem.

While not basal regulators of normal blood pressure, endocannabinoids mediate blood pressure drops during shock, affect blastocyst implantation in reproduction, and modulate anxiety and memory extinction. Friede et al. noted that excessive stimulation of CB-1 receptors on the fertilized blastocyst and uterus can block implantation or cause early abortion.

Inhibitors of FAAH and DAG lipase attempt to enhance endogenous cannabinoid actions selectively, but clinical trials have encountered setbacks, including serious adverse effects and clinical trial failures. Enserink and Mallet described how deaths and serious adverse effects in volunteers receiving a FAAH inhibitor in a Phase I trial clouded the profile of these compounds.

10 Key Ideas

1. Cannabis contains over one hundred cannabinoid chemicals in specialized glandular structures, with delta-9-tetrahydrocannabinol acting as the main psychoactive agent.
2. The criminalization of marijuana in the United States was driven by political campaigns in the 1930s that led to a federal ban and halted scientific research for decades.
3. The isolation of delta-9-THC and the subsequent discovery of specific G-protein coupled cannabinoid receptors revealed the molecular basis of cannabis action in the brain.
4. The route of administration drastically alters the pharmacokinetics, bioavailability, and subjective intensity of cannabis effects.
5. The identification of specific G-protein coupled cannabinoid receptors explained how tiny physiological amounts of THC produce profound psychoactive effects.
6. Cannabinoids alter neurotransmitter release, cardiovascular function, and cognitive processes, producing a distinct spectrum of subjective intoxication and behavioral changes.
7. Cannabis produces consistent acute disruptions in short-term working memory and executive function, while subjective highs progress through euphoria and altered time perception.
8. The brain produces its own endogenous cannabinoid ligands that serve as retrograde messengers to regulate synaptic transmission, energy metabolism, and pain.
9. Released from postsynaptic neurons, these lipid messengers travel back to presynaptic terminals to suppress both inhibitory and excitatory inputs, a mechanism underlying phenomena like depolarization-induced suppression of inhibition.
10. Hypothalamic endocannabinoids and receptors in fat tissues, liver, and pancreas control energy metabolism, insulin secretion, and the balance between hunger and satiety hormones.